Allergan v Merz Pharma UK Ltd: Xeomin promotion claims on complexing proteins and dosing ratio

📊

Key facts

⌄

Case number	AUTH/2119/4/08
Case reference	Not stated
Complainant	Allergan Ltd
Respondent/company	Merz Pharma UK Ltd
Product(s)	Xeomin; Botox
Material/channel	BMJ advertisement; leavepiece; stand panels (ABN conference exhibition)
Key issue	Misleading implied comparisons about complexing proteins; absolute efficacy statements amid scientific debate; 1:1 dosing ratio claims without clarifying non-interchangeability per SPC; refrigeration/cold chain claim assessed for disparagement
Dates (received/completed if stated)	Complaint received 30 April 2008; case completed 2 July 2008
Appeal	Not stated
Code year	Not stated
Breaches/clauses	Clause 7.2 (breach) for “Neurotoxin you need – complexing proteins you don’t”; Clause 7.2 (breach) for “complexing proteins have no therapeutic effect”; Clauses 3.2 and 7.2 (breaches) for 1:1 dosing ratio claims; Clause 8.1 (no breach) for refrigeration/cold chain claim
Sanctions	No explicit additional sanctions stated beyond the required undertaking/corrective actions described in the report

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

Allergan Ltd complained about Merz Pharma UK Ltd’s promotion of Xeomin (clostridium botulinum neurotoxin type A, free of complexing proteins).
Materials at issue: a BMJ advertisement (ref 1012a/XEO/NOV/2007/BB), a leavepiece (ref 10/10/XEO/NOV/2007/BB), and stand panels used at the Association of British Neurologists (ABN) conference in Dublin, 26–28 March 2008.
Merz confirmed the Dublin materials were within the scope of the Code and said they were over-stickered to reflect licensed status in Ireland; the leavepiece without that modification had been used in the UK, and the exhibition panels had also been used at a UK launch meeting.
Allergan (supplier of Botox) challenged: (1) the claim “Neurotoxin you need – complexing proteins you don’t”; (2) the claim about no refrigeration “reducing the risk of therapy failure or product wastage due to a gap in the cold chain”; (3) the claim “Therapeutic efficacy is solely a characteristic of the Botulinum neurotoxin – complexing proteins have no therapeutic effect”; and (4) claims implying a 1:1 dosing ratio with Botox without clarifying non-interchangeability of units per the Xeomin SPC.

⚖️

⌄

The Panel ruled the claim “Neurotoxin you need – complexing proteins you don’t” was misleading (implied a proven clinical disadvantage for products with complexing proteins without supporting data) and breached the Code.
The Panel ruled the refrigeration/cold chain claim was not unreasonable given the Xeomin SPC and was not disparaging; no breach was found for that allegation.
The Panel ruled “Therapeutic efficacy is solely a characteristic of the botulinum neurotoxin – complexing proteins have no therapeutic effect” was misleading (did not reflect ongoing scientific/clinical debate) and breached the Code.
The Panel ruled the 1:1 dosing ratio claims in the leavepiece were misleading and inconsistent with the Xeomin SPC because they did not make clear that unit doses were not interchangeable; breaches were ruled.
Complaint received: 30 April 2008. Case completed: 2 July 2008.

📖

⌄

Clause 7.2: Breach ruled for “Neurotoxin you need – complexing proteins you don’t”.
Clause 8.1: No breach ruled for the refrigeration/cold chain claim.
Clause 7.2: Breach ruled for “Therapeutic efficacy is solely a characteristic of the botulinum neurotoxin – complexing proteins have no therapeutic effect”.
Clauses 3.2 and 7.2: Breaches ruled for the 1:1 dosing ratio claims due to lack of clarity on non-interchangeability of unit doses per the SPC.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access